Guanfacine Tablet, Extended Release
Product Images NDC 70518-2771

6 FDA label images from Remedyrepack Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Guanfacine (NDC 70518-2771). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure-1.jpg (Figure 1)

Figure-1.jpg (Figure 1)
A line graph comparing guanfacine plasma concentration (ng/mL) over 24 hours for Guanfacine Extended-Release Tablets 1 mg QD and Tenex 1 mg QD. The y-axis shows concentration from 0 to 4 ng/mL, while the x-axis shows time in hours from 0 to 24. Guanfacine Extended-Release tablets show a gradual increase and slower decline compared to Tenex.*
FDA Label Image

Figure-2.jpg (Figure 2)

Figure-2.jpg (Figure 2)
A pharmacokinetic chart displaying fold changes with 90% confidence intervals in Cmax and AUC values relative to reference levels. It compares the effects of CYP3A4/5 inhibitors (Ketoconazole, Fluconazole) and CYP3A4 inducers (Rifampin, Efavirenz), as well as Oral Methylphenidate and Lisdexamfetamine Dimesylate, on drug exposure parameters.*
FDA Label Image

Figure-3.jpg (Figure 3)

Figure-3.jpg (Figure 3)
A pharmacokinetic comparison chart showing fold change and 90% confidence intervals of Cmax and AUC for two interacting drugs, Oral Methylphenidate and Lisdexamfetamine Dimesylate, relative to a reference. The horizontal axis represents change relative to the reference from 0.0 to 2.0.*
FDA Label Image

Figure-4.jpg (Figure 4)

Figure-4.jpg (Figure 4)
A line graph depicting time to treatment failure over days for two groups: one receiving a placebo and the other labeled SPD603. The vertical axis shows the treatment failure percentage, and the horizontal axis shows time in days up to 210 days. The placebo group shows a higher treatment failure rate than the SPD603 group over time.*
FDA Label Image

Guanfacine 1mg 70518 2771 00

Guanfacine 1mg 70518 2771 00
Label for Guanfacine Extended-Release 1 mg tablet. The label shows a quantity of 30 tablets and states the tablet should not be crushed, chewed, or broken before swallowing. It is labeled as RX only and repackaged by RemedyRepack Inc. The manufacturer listed is TWI Pharmaceuticals USA, Paramus, NJ.*
FDA Label Image

Molecular-structure.jpg (Molecular Structure)

Molecular-structure.jpg (Molecular Structure)
Chemical structure of guanfacine hydrochloride, the active ingredient in Guanfacine Extended-Release tablets. The diagram shows the molecular arrangement including chlorines, nitrogen, and hydrogen atoms as part of the compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.